🚨 Exciting times for the #NET community! Positive Phase III #ACTION1 results with ²²⁵Ac-DOTATATE after progression on ¹⁷⁷Lu! A major milestone for alpha-emitting radioligand therapy and potentially a new chapter in #NET treatment sequencing. But why does this matter? 🧵👇 🎯 Same target, different radiation! 🔵 ¹⁷⁷Lu (Lutetium): Beta emitter, longer tissue range, lower linear energy transfer (LET). 🔴 ²²⁵Ac (Actinium): Alpha emitter, very short range, much higher LET and potentially more lethal DNA double-strand damage. Not simply a stronger lutetium! 📊 #ACTION1 reports significantly improved PFS versus standard-of-care options in SSTR+ GEP-NETs progressing after ¹⁷⁷Lu. Very encouraging! 👏 But let's see the full data: HR, absolute PFS benefit, long-term toxicity, OS and quality of life. And important questions remain: ⚠️ Cumulative renal and bone marrow toxicity 🏭 Isotope production and availability 🚚 Manufacturing, logistics and equitable access 🔬 Optimal sequencing and patient selection 🌍 Perfect timing for #ESMO26 in Madrid! 📅 Sunday, October 25 🕝 14:45–16:15 📍 Leon Auditorium, Hall 4 Join us for our educational session on radioligand therapy in advanced NETs, with @Ja_Capdevila and an outstanding international faculty! @OncoThor @RachelRiechelm2 Looking forward to discussing how we can translate these advances into better outcomes for our patients. See you all at #ESMO26 in Madrid! 🇪🇸🤝 @myESMO @Netespana @_SEOM

¿Sabías que la nutrición influye directamente en cómo se tolera el tratamiento oncológico y en la recuperación? El 15 de septiembre, reunión abierta sobre nutrición en el paciente con cáncer en el Hospital Ruber Juan Bravo (Madrid). Abierto a pacientes, familias y público general. 📅 15 de septiembre | 15,30 a 18,00 h Con el apoyo de @Nutricia_es @quironsalud #Nutrición #Cáncer #NutriciónOncológica #Quironsalud